Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 19/20 | 0.57 |
| ▸ | RBBP4 | Q09028 | 19/20 | 0.57 |
| ▸ | SUZ12 | Q15022 | 19/20 | 0.57 |
| ▸ | EZH2 | Q15910 | 19/20 | 0.57 |
| ▸ | AEBP2 | Q6ZN18 | 19/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19018448 | 0.88 | EZH2 (0.58) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16212957 | 0.87 | EZH2 (0.57) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16212959 | 0.87 | EZH2 (0.57) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16212866 | 0.86 | EZH2 (0.56) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16213269 | 0.86 | EED (0.57) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16213270 | 0.86 | EED (0.57) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16212822 | 0.78 | EED (0.62) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL18555891 | 0.77 | EZH2 (0.42) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL18555890 | 0.77 | EZH2 (0.42) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL16225006 | 0.76 | EZH2 (0.57) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790212-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-9505745-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| EP-2991980-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014177982-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177982-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102083-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | EED 5/4885RBBP4 190/4885SUZ12 4/4885 |
| US-20170029412-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | EED 5/4885RBBP4 190/4885SUZ12 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.